Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thimerosal provision has short shelf-life

Executive Summary

Omnibus appropriations bill expected to repeal provision in homeland security bill which required that claims related to vaccine components, including the preservative thimerosal, go through the Vaccine Injury Compensation Fund (1"The Pink Sheet" Nov. 18, 2002, p. 27). Sens. Lincoln Chafee (R-R.I.), Susan Collins (R-Maine), and Olympia Snowe (R-Maine) announce they have secured an agreement for the Senate to consider comprehensive legislation on overhauling the injury compensation system and encouraging vaccine development. The thimerosal provision was part of a broader bill sponsored by Senate Majority Leader Bill Frist (Tenn.)...

You may also be interested in...



Vaccine Definition Refined In Homeland Security Bill To Include Thimerosal

Vaccines are defined as including all components and ingredients listed in product license applications under the Homeland Security Act

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel